Immunosuppressive Phenotype and Poor I/O Agent Response Correlation

While checkpoint inhibitors are proving highly successful in oncology, a large proportion of patients do not respond to these treatments. This is due to the extreme heterogeneity of patient tumors, prompting a strong desire to identify biomarkers, both genetic and immunological, which could predict clinical benefit.